Emerging Immunotargets and Immunotherapies in Prostate Cancer Article

Full Text via DOI: 10.2174/1389450117666160217123304 PMID: 26898309 Web of Science: 000374119900005
International Collaboration

Cited authors

  • Montironi, Rodolfo; Santoni, Matteo; Sotte, Valeria; Cheng, Liang; Lopez-Beltran, Antonio; Massari, Francesco; Matrana, Marc R.; Moch, Holger; Berardi, Rossana; Scarpelli, Marina


  • Innate and adaptive immunity are both involved in prostate cancer (PCa) carcinogenesis and progression. On this scenario, several immunotherapeutic approaches have been proposed and are presently under extensive investigation in PCa patients. Among emerging immune targets, immune checkpoint inhibitors such as anti-cytotoxic T-lymphocyteassociated protein 4 (CTLA-4), anti-Programmed death-1 (PD-1) and anti-Programmed death-ligand-1 (PD-L1) agents seem to represent the most promising candidate for these patients, together with oncolytic viruses and vaccines, used alone or in combined strategies. In this review, we focused on emerging immunotherapeutic approaches in patients with PCa, showing the rational for their association with current standard therapies including anti-androgen agents, chemo-or radiation therapy.

Publication date

  • 2016

Published in

International Standard Serial Number (ISSN)

  • 1389-4501

Start page

  • 777

End page

  • 782


  • 17


  • 7